Form 4: Benitec Biopharma Inc. Grants Stock Options to Board Member

Benitec Biopharma Inc. granted stock options to board member Kishan Mehta, which will vest no later than December 9, 2025.

Summary

• Benitec Biopharma Inc. granted 35,000 stock options to Kishan Mehta, a member of the company's Board of Directors.
• These options are for the purchase of common stock and were awarded in connection with his role on the board.
• Mr. Mehta is holding these options for the benefit of Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd.
• The options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 9, 2025.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of granting stock options to board members, which is generally viewed positively for aligning interests. There are no indications of negative sentiment.

Positives

• The grant of stock options aligns the interests of the board member with the company's performance.
• The vesting schedule encourages long-term commitment from the board member.

Risks

• The vesting of the options could potentially dilute existing shareholders' equity if exercised.

Management Comments

• Mr. Mehta, as Portfolio Manager for Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd, is holding such options for the benefit of the Funds.

Industry Context

Granting stock options to board members is a common practice in the biotechnology industry to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for board members in publicly traded companies, particularly in the biotech sector.
• The vesting period of up to one year is typical for such grants, aligning with the company's annual performance cycle.
• Companies like Amgen, Gilead, and Biogen also use stock options as part of their board compensation packages.

Stakeholder Impact

• Shareholders may experience minor dilution if the options are exercised.
• The grant of options is intended to align the board member's interests with the company's success, which is beneficial for all stakeholders.

Next Steps

• The options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 9, 2025.

Key Dates

Keywords

stock options, board of directors, equity compensation, vesting, common stock, Benitec Biopharma